» Articles » PMID: 20051569

Antidepressant Drug Effects and Depression Severity: a Patient-level Meta-analysis

Overview
Journal JAMA
Specialty General Medicine
Date 2010 Jan 7
PMID 20051569
Citations 563
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Antidepressant medications represent the best established treatment for major depressive disorder, but there is little evidence that they have a specific pharmacological effect relative to pill placebo for patients with less severe depression.

Objective: To estimate the relative benefit of medication vs placebo across a wide range of initial symptom severity in patients diagnosed with depression.

Data Sources: PubMed, PsycINFO, and the Cochrane Library databases were searched from January 1980 through March 2009, along with references from meta-analyses and reviews.

Study Selection: Randomized placebo-controlled trials of antidepressants approved by the Food and Drug Administration in the treatment of major or minor depressive disorder were selected. Studies were included if their authors provided the requisite original data, they comprised adult outpatients, they included a medication vs placebo comparison for at least 6 weeks, they did not exclude patients on the basis of a placebo washout period, and they used the Hamilton Depression Rating Scale (HDRS). Data from 6 studies (718 patients) were included.

Data Extraction: Individual patient-level data were obtained from study authors.

Results: Medication vs placebo differences varied substantially as a function of baseline severity. Among patients with HDRS scores below 23, Cohen d effect sizes for the difference between medication and placebo were estimated to be less than 0.20 (a standard definition of a small effect). Estimates of the magnitude of the superiority of medication over placebo increased with increases in baseline depression severity and crossed the threshold defined by the National Institute for Clinical Excellence for a clinically significant difference at a baseline HDRS score of 25.

Conclusions: The magnitude of benefit of antidepressant medication compared with placebo increases with severity of depression symptoms and may be minimal or nonexistent, on average, in patients with mild or moderate symptoms. For patients with very severe depression, the benefit of medications over placebo is substantial.

Citing Articles

Efficacy and safety of electroacupuncture on treating mild to moderate first-episode depression: a study protocol for a randomized controlled trial.

Xia J, Jiang M, Yin X, Wang Z, Li F, Wei H Front Psychiatry. 2025; 16:1521859.

PMID: 40078528 PMC: 11897229. DOI: 10.3389/fpsyt.2025.1521859.


The Role of Music in Psychedelic-Assisted Therapy: A Comparative Analysis of Neuroscientific Research, Indigenous Entheogenic Ritual, and Contemporary Care Models.

Efthimiou A, Cardinale A, Kepa A Psychedelic Med (New Rochelle). 2025; 2(4):221-233.

PMID: 40051482 PMC: 11658384. DOI: 10.1089/psymed.2023.0058.


Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development.

Weintraub M, Jeffrey J, Grob C, Ichinose M, Bergman R, Cooper Z Psychedelic Med (New Rochelle). 2025; 1(4):230-240.

PMID: 40046861 PMC: 11658652. DOI: 10.1089/psymed.2023.0018.


Effect of DLPFC rTMS on anhedonia and alpha asymmetry in depressed patients.

Kazemi R, Rostami R, Hadipour A, Zandbagleh A, Khomami S, Kiaee N Sci Rep. 2025; 15(1):899.

PMID: 39762503 PMC: 11704047. DOI: 10.1038/s41598-024-85057-w.


Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials.

Saelens J, Gramser A, Watzal V, Zarate Jr C, Lanzenberger R, Kraus C Neuropsychopharmacology. 2024; .

PMID: 39739012 DOI: 10.1038/s41386-024-02044-5.


References
1.
Wichers M, Barge-Schaapveld D, Nicolson N, Peeters F, de Vries M, Mengelers R . Reduced stress-sensitivity or increased reward experience: the psychological mechanism of response to antidepressant medication. Neuropsychopharmacology. 2008; 34(4):923-31. DOI: 10.1038/npp.2008.66. View

2.
DeRubeis R, Hollon S, Amsterdam J, Shelton R, Young P, Salomon R . Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry. 2005; 62(4):409-16. DOI: 10.1001/archpsyc.62.4.409. View

3.
Liebowitz M, Manley A, Padmanabhan S, Ganguly R, Tummala R, Tourian K . Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008; 24(7):1877-90. DOI: 10.1185/03007990802161923. View

4.
Lima M, Hotoph M, Wessely S . The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis. Psychol Med. 2000; 29(6):1273-89. DOI: 10.1017/s0033291799001324. View

5.
Liebowitz M, Yeung P, Entsuah R . A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007; 68(11):1663-72. DOI: 10.4088/jcp.v68n1105. View